<unk> , sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020,<unk>  is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.<unk>  was developed by Chengdu Kanghong Biotech Company in the People’s Republic of China and is marketed under the name Lumitin.
Conbercept
Psychon 
Stimming
Retractor 
Lint 
Parapsychology
Therapeutic touch
Auxology